Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Raludotatug deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with CDH6 expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab Raludotatug […]
Weekly Digest – September 2025 Weekly Digest – September 2025 16 September 2025: FDA grants Fast Track Designation to Corbus Pharmaceuticals Nectin-4 targeting ADC CRB-701 in head and neck squamous cell carcinoma Corbus Pharmaceuticals announced that the FDA granted Fast […]
Weekly Digest – September 2025 Weekly Digest – September 2025 17 September 2025: Hengrui Medicine has received its marketing authorization application for a new indication for its Ruikang trastuzumab injection and has been included in the priority review process Hengrui […]
Weekly Digest – September 2025 Weekly Digest – September 2025 16 September 2025: Adagene expands SAFEbody collaboration and license agreement with Exelixis to develop third novel masked antibody-drug conjugate Adagene announced an amendment to its 2021 collaboration and license agreement with […]
Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Spera Pharma and Mycenax forge strategic alliance to streamline ADC drug substance and drug product manufacturing services Spera Pharma and Mycenax Biotech have formed a strategic alliance […]
Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Biocytogen announces ADC innovator Tubulis has signed global exclusive license agreement for single antibody Biocytogen announced that Tubulis has exercised an exclusive license for the global development […]
